Healthcare Industry News: Versaport
News Release - October 15, 2008
Covidien Introduces Versaport(TM) Plus Bladeless Trocars to Surgical Markets Globally
Innovative Trocar Line Features Proprietary Technology that Delivers a Range of Clinical BenefitsNORTH HAVEN, Conn.--(HSMN NewsFeed)--Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, today announced that its Surgical Devices business unit has launched the Versaport™ Plus Bladeless Trocar line for the minimally invasive surgical market worldwide.
The Versaport™ Plus Bladeless Trocars offer surgeons greater precision and control, low insertion force, a small facial defect and superior port fixation with Covidien’s proprietary secure entry technology. When the Versaport™ Plus Bladeless Trocar is combined with Step™ technology in VersaStep™ Plus, Covidien sets the standard for safety in laparoscopic entry and provides medical professionals with a comprehensive line of bladeless access devices.
“Our innovative Versaport™ Plus Bladeless Trocars are the latest example of Covidien’s collaboration with customers to offer access solutions that give them the sense of confidence, security and control that they have been asking for,” said Scott Flora, President, Surgical Devices, Covidien. “This product launch, when coupled with some of our current technologies, significantly enhances our position in the rapidly growing market for bladeless access devices and trocars.”
Versaport™ Plus Bladeless Trocars can be used in conventional and advanced laparoscopic procedures in general, bariatric, colon and rectal, gynecological and urological surgery.
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2007 revenue of nearly $9 billion, Covidien has more than 42,000 employees worldwide in 57 countries, and its products are sold in over 130 countries. Please visit www.covidien.com to learn more about our business.
Source: Covidien
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!